Clinical trials: Locoregional Neoplasm Recurrence
Adenocarcinoma of the Bladder, Distal Urethral Cancer
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
This phase II trial is studying how well sorafenib works in treating patients with progressive regional or metastatic cancer of the urothelium.
- Conditions
- Adenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer
- Trial name
- NCT00112905
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Carcinoid Tumor, Islet Cell Carcinoma
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
RATIONALE: Vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor. Octreotide may help control symptoms, such as diarrhea, caused by the tumor.
- Trial name
- NCT00227773
- Testing
- octreotide acetate, vatalanib, anti-cytokine therapy
- Sponsor
- Eastern Cooperative Oncology Group
Prostate Cancer, Oligometastasis
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate…
- Conditions
- Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer
- Trial name
- VA STARPORT (NCT04787744)
- Testing
- PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease
- Where
- 20 sites in United States
- Volunteers
- 378 people
- Sponsor
- VA Office of Research and Development
Breast Cancer
DianaWeb: Before and After Study Online Based Participatory Research on Breast Cancer Women
DianaWeb is a community-based participatory research (CBPR) offered to Italian breast cancer patients. The aim of the study is the evaluation of effectiveness of a lifestyle and nutrition intervention to improve the prognosis.
- Trial name
- DianaWeb (NCT05057598)
- Testing
- Community-based participatory research on diet and lifestyle
- Where
- Italy
- Volunteers
- 50,000 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Cancer
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by…
- Trial name
- NCT00016380
- Testing
- dexamethasone, ondansetron, quality-of-life assessment
- Where
- 14 sites in Canada
- Volunteers
- 211 people
- Sponsor
- NCIC Clinical Trials Group
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer
This pilot phase I trial studies the side effects and best way to give stereotactic body radiation therapy and T-cell infusion in treating patients with metastatic kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01943188
- Testing
- stereotactic body radiation therapy, cyclophosphamide, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stanford University
Circumferential Resection Margin, Intraoperative Perforation of Rectum
Surgery Without Neoadjuvant Chemoradiotherapy Compared With Neoadjuvant Chemoradiotherapy for Rectal Cancer With Negative Circumferential Resection Margin Based on MRI Assessment, a Perspective Multicenter Randomized Controlled Trial
For now, neoadjuvant chemoradiotherapy is routinely performed for T3N1-2M0 rectal cancer. However, there are lots of complications following neoadjuvant chemoradiotherapy, such as Wound-related complications, anastomotic leakage…
- Conditions
- Circumferential Resection Margin, Intraoperative Perforation of Rectum, Local Recurrence of Malignant Tumor of Rectum, Disease-free Survival
- Trial name
- SCRM-01 (NCT03504449)
- Testing
- neoadjuvant chemoradiotherapy
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Beijing Chao Yang Hospital
Liver Cancer, Cancer, Treatment-Related
Unravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence?
Radiofrequency devices have been increasingly employed in liver surgery in order to achieve proper hemostasis and this use has become more evident with the implementation of minimal invasive surgery.
- Trial name
- LIVERaTION (NCT05492136)
- Testing
- Additional margin coagulation
- Where
- Spain
- Volunteers
- 720 people
- Sponsor
- Hospital del Mar
Sentinel Lymph Node Biopsy, Locoregional Neoplasm Recurrence
SLNB After Neoadjuvant Treatment in Node Positive Patients
From May 2016 till May 2018 all breast cancer patients with operable disease submitted to surgery after neoadjuvant treatment would be divided in four groups considering initially clinical axillary stage, axillary procedure that…
- Conditions
- Sentinel Lymph Node Biopsy, Locoregional Neoplasm Recurrence, Progression, Disease
- Trial name
- NCT03833960
- Volunteers
- 65 people
- Sponsor
- Clinical Hospital Center Rijeka
Prostatic Neoplasms, Biochemical Recurrence
Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)
The goal of this clinical trial is to learn if adding metastasis-directed radiotherapy with or without pelvic salvage radiotherapy, to intermittent prostate cancer drugs (intensified hormone therapy) can delay the need to restart…
- Conditions
- Prostatic Neoplasms, Biochemical Recurrence, Oligometastatic Prostate Cancer
- Trial name
- ESCALATE-RT (NCT07782112)
- Testing
- Radiotherapy for MDT ± WPRT, Androgen Deprivation Therapy (ADT), Enzalutamide
- Where
- 19 sites in Belgium, France and 1 more
- Volunteers
- 140 people
- Sponsor
- Ente Ospedaliero Cantonale, Bellinzona
Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well vorinostat works in treating patients with locally recurrent or metastatic cancer of…
- Conditions
- Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00363883
- Testing
- vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Liver Metastases
COLLISION RELAPSE Trial
The primary objective is to demonstrate superiority of neoadjuvant systemic therapy followed by repeat local treatment as compared to upfront repeat local treatment in patients with at least one locally treatable recurrent CRLM…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Chemotherapy Effect
- Trial name
- NCT05861505
- Testing
- Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B), Repeat local treatment
- Where
- Netherlands
- Volunteers
- 360 people
- Sponsor
- Amsterdam UMC, location VUmc
Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
This phase II trial studies the effect of re-irradiation with NBTXR3 in combination with pembrolizumab in treating patients with head and neck squamous cell cancer that cannot be removed by surgery (inoperable) and has come back…
- Trial name
- NCT04834349
- Testing
- Hafnium Oxide-containing Nanoparticles NBTXR3, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma
RATIONALE: Ethanol-lock treatment may help prevent central venous catheter infections in patients with high-risk neuroblastoma. PURPOSE: This phase I trial is studying the side effects of ethanol-lock treatment in preventing…
- Trial name
- NCT00471679
- Testing
- ethanol
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Childhood Langerhans Cell Histiocytosis, Fanconi Anemia
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia, Lymphoma
- Trial name
- NCT00084695
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Milton S. Hershey Medical Center
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Ipilimumab and Local Radiation for Selected Solid Tumors
This pilot phase 1-2 trial studies the side effects and best of dose ipilimumab when given together with local radiation therapy and to see how well it works in treating patients with recurrent melanoma, non-Hodgkin lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01769222
- Testing
- Ipilimumab, Radiation therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Neuroblastoma
Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy may kill more tumor cells.
- Trial name
- NCT00410631
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- 80 sites in Germany, Switzerland
- Volunteers
- 642 people
- Sponsor
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
Carcinoma, Hepatocellular
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or local ablation).
- Trial name
- STORM (NCT00692770)
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 199 sites in United States, Argentina and 26 more
- Volunteers
- 1,114 people
- Sponsor
- Bayer
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
This phase II trial is studying how well sorafenib works in treating patients with advanced or metastatic cancer of the urinary tract.
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00112671
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Neoplasms, Neoplasm Recurrence, Local
Incidence, Risk Factor, Treatment and Overall Survival of Locally Recurrent Rectal Cancer
Data on disease recurrence was collected for all primary rectal cancer patients diagnosed in the Netherlands over the first six months of 2015.
- Trial name
- NCT05475301
- Volunteers
- 1,431 people
- Sponsor
- Radboud University Medical Center